Analysts Set Henry Schein, Inc. (NASDAQ:HSIC) Price Target at $76.92

Henry Schein, Inc. (NASDAQ:HSIC) has received an average rating of “Hold” from the fourteen ratings firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $76.9231.

A number of equities analysts recently commented on the company. Morgan Stanley lifted their price target on Henry Schein from $55.00 to $58.00 and gave the stock an “underweight” rating in a research note on Wednesday, November 5th. Barclays initiated coverage on Henry Schein in a report on Monday, December 8th. They set an “overweight” rating and a $86.00 target price on the stock. Barrington Research set a $79.00 target price on Henry Schein and gave the stock an “outperform” rating in a research report on Wednesday, November 5th. Wall Street Zen upgraded Henry Schein from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Finally, Wells Fargo & Company raised their price objective on Henry Schein from $70.00 to $76.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 5th.

Henry Schein Stock Performance

Shares of HSIC opened at $76.44 on Friday. The firm has a market cap of $9.00 billion, a price-to-earnings ratio of 24.19, a PEG ratio of 2.33 and a beta of 0.89. The company has a quick ratio of 0.79, a current ratio of 1.40 and a debt-to-equity ratio of 0.54. The business’s 50 day moving average is $72.04 and its two-hundred day moving average is $70.00. Henry Schein has a 52-week low of $60.56 and a 52-week high of $82.49.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $1.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.27 by $0.11. The firm had revenue of $3.34 billion for the quarter, compared to analysts’ expectations of $3.28 billion. Henry Schein had a net margin of 3.02% and a return on equity of 14.76%. Henry Schein has set its FY 2025 guidance at 4.880-4.960 EPS. Analysts forecast that Henry Schein will post 4.74 EPS for the current fiscal year.

Institutional Investors Weigh In On Henry Schein

Several institutional investors and hedge funds have recently bought and sold shares of HSIC. MAI Capital Management raised its stake in Henry Schein by 7.5% during the 3rd quarter. MAI Capital Management now owns 2,061 shares of the company’s stock valued at $137,000 after acquiring an additional 144 shares in the last quarter. Vanguard Personalized Indexing Management LLC increased its holdings in shares of Henry Schein by 3.5% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 4,669 shares of the company’s stock valued at $341,000 after purchasing an additional 157 shares during the period. Equitable Trust Co. raised its stake in shares of Henry Schein by 3.1% during the second quarter. Equitable Trust Co. now owns 5,317 shares of the company’s stock valued at $388,000 after purchasing an additional 158 shares in the last quarter. CW Advisors LLC raised its stake in shares of Henry Schein by 2.8% during the second quarter. CW Advisors LLC now owns 5,913 shares of the company’s stock valued at $432,000 after purchasing an additional 163 shares in the last quarter. Finally, TD Asset Management Inc lifted its holdings in Henry Schein by 0.8% in the second quarter. TD Asset Management Inc now owns 22,016 shares of the company’s stock worth $1,608,000 after purchasing an additional 164 shares during the period. Institutional investors and hedge funds own 96.62% of the company’s stock.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.